Melbourne researchers are homing in on a new target for malaria treatment, after developing a compound that blocks the action of a key 'gatekeeper' enzyme essential for malaria parasite survival.

The compound, called WEHI-916, is the first step toward a new class of antimalarial drugs that could cure and prevent malaria infections caused by all species of the parasite, including those resistant to existing drugs.

Read more: [ Ссылка ]

свернуть